Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 3
1997 2
1998 3
1999 1
2001 1
2003 2
2004 1
2008 1
2009 1
2010 1
2017 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer.
Artal-Cortés A, Gomez-Codina J, Gonzalez-Larriba JL, Barneto I, Carrato A, Isla D, Camps C, Garcia-Giron C, Font A, Meana A, Lomas M, Vadell C, Arrivi A, Alonso C, Maestu I, Campbell J, Rosell R. Artal-Cortés A, et al. Among authors: vadell c. Clin Lung Cancer. 2004 Nov;6(3):175-83. doi: 10.3816/clc.2004.n.031. Clin Lung Cancer. 2004. PMID: 15555219 Clinical Trial.
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
Cardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Cardenal F, et al. Among authors: vadell c. J Clin Oncol. 1999 Jan;17(1):12-8. doi: 10.1200/JCO.1999.17.1.12. J Clin Oncol. 1999. PMID: 10458212 Clinical Trial.
Screening for epidermal growth factor receptor mutations in lung cancer.
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group. Rosell R, et al. N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19. N Engl J Med. 2009. PMID: 19692684 Free article.
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado A, Azagra P, Jiménez U, González-Larriba JL, Diz P, Cardenal F, Artal A, Carrato A, Morales S, Sanchez JJ, de las Peñas R, Felip E, López-Vivanco G; Spanish Lung Cancer Group. Alberola V, et al. Among authors: vadell c. J Clin Oncol. 2003 Sep 1;21(17):3207-13. doi: 10.1200/JCO.2003.12.038. J Clin Oncol. 2003. PMID: 12947054 Clinical Trial.
Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.
Remon J, Isla D, Garrido P, de Castro J, Majem M, Viñolas N, Artal A, Carcereny E, García-Campelo MR, Lianes P, Provencio M, Juan O, Diz P, Blanco R, Lopez-Castro R, Maestu I, Vadell C, Felip E. Remon J, et al. Among authors: vadell c. Clin Transl Oncol. 2017 Dec;19(12):1537-1542. doi: 10.1007/s12094-017-1700-8. Epub 2017 Jun 28. Clin Transl Oncol. 2017. PMID: 28660482
18 results